Evaluation of the effectiveness of additional risk minimisation measures (aRMMs) that aim to reduce the risks of phototoxicity, squamous cell carcinoma (SCC) of the skin and hepatic toxicity in patients receiving voriconazole in the European Union (EU)

29/07/2015
22/02/2024
EU PAS number:
EUPAS10428
Study
Finalised
Subscribe
Download as PDF
Documents
Study protocol
Initial protocol

A1501102_VFEND aRMM evalution survey PROTOCOL_FINAL REDACTED_7_28_2015_B

English (341.59 KB - PDF) View document
Updated protocol

A1501102_PROTOCOL AND APPROVAL_NIS_08JULY2015_FINAL_part1

First published: 22/02/2024
English (637.76 KB - PDF) View document
Study results
Study results

a1501102-report-body_1

English (1.41 MB - PDF) View document
Study report
Study report

a1501102-abstract

English (1.9 MB - PDF) View document
Other information
Study, other information

A1501102_PROTOCOL AND APPROVAL_NIS_08JULY2015_FINAL_part2

English (1.68 MB - PDF) View document

A1501102_PROTOCOL AND APPROVAL_NIS_08JULY2015_FINAL_part3

English (1.16 MB - PDF) View document